Tekmira rises on positive Ebola drug data
This article was originally published in Scrip
Executive Summary
Shares of Tekmira jumped 6.7% on 23 April after researchers reported positive preclinical data for the firm's experimental Ebola drug, TKM-Ebola-Guinea, which contains an "adjusted" siRNA cocktail.